<?xml version="1.0" encoding="UTF-8"?>
<p id="p-5bbc02b062ef527a848c60ea44b1c16a">Chloroquine phosphate is an antimalarial drug. By increasing the pH of the nucleus, it can inhibit both the virus-host cell interaction and the pH-dependent virus replication
 <sup>
  <xref rid="R5495" id="xref-fbe5dfda005943879aaa38355996314d" ref-type="bibr">7</xref>
 </sup>. The results from 
 <italic>in vitro</italic> studies suggest that chloroquine can actively inhibit SARS-COV-2
 <sup>
  <xref rid="R5492" id="xref-969900b98d50fa2ffc50a1510d326af9" ref-type="bibr">4</xref>
 </sup>. Both animal experiments and clinical trials are currently in progress. Results from preliminary clinical trials show that chloroquine phosphate has promising effects on patients with COVID-19. Of note, it has been reported that chloroquine may cause adverse reactions such as ocular disorders, immune system disorders, ear and labyrinth disorders, cardiac disorders, etc.
 <sup>
  <xref rid="R5496" id="xref-6bd69d20652c8af1f1d13cf1c8bcd5c9" ref-type="bibr">8</xref>
 </sup>, therefore precautions and further testing are needed for the safe and effective treatment in COVID-19 patients.
</p>
